Shilpa Medicare Q4FY26 profit jumps 645% to ₹108 crore

Snapshot: a sharp jump in quarterly earnings

Shilpa Medicare reported a strong surge in consolidated profitability for Q4FY26, supported by faster revenue growth, improved operating performance, and an exceptional one-time gain. The company posted consolidated net profit of ₹108 crore for the quarter, up from ₹14.5 crore in the corresponding quarter last year. That translates into a year-on-year increase of nearly 645%.

Revenue from operations rose 32% year-on-year to ₹437 crore, compared with ₹331 crore a year ago. The quarter also showed stronger operating leverage, with EBITDA growth outpacing revenue growth. The set of numbers points to a quarter where both the core business and non-recurring items played a role in the reported profit outcome.

Revenue growth: momentum across segments, as reported

The company’s Q4FY26 revenue from operations came in at ₹437 crore, up from ₹331 crore in Q4FY25. The company did not break down segment-wise performance in the provided data, but the topline increase was described as reflecting “healthy business momentum across segments.”

For investors, the key takeaway from the topline is the 32% year-on-year expansion, which provided a base for operating profit to grow faster. The scale-up also matters because margin expansion in pharma businesses often depends on product mix, utilization, and cost absorption across manufacturing and development operations.

Operating performance: EBITDA rises, margins expand

Shilpa Medicare’s EBITDA climbed 49.6% year-on-year to ₹119.7 crore from ₹80 crore in Q4FY25. With EBITDA growth running ahead of revenue growth, the company reported an improvement in operating margin.

EBITDA margin expanded to 27.4% in Q4FY26 from 24.1% in the year-ago quarter. The company attributed the improvement to better operational efficiency and cost management. While the data does not provide a detailed cost line analysis, the margin move suggests a combination of higher contribution from profitable lines, improved fixed cost absorption, or both.

One-time items: a swing from loss to gain

A notable driver of the reported year-on-year profit change was the movement in exceptional items. Shilpa Medicare recorded a one-time gain of ₹25 crore in Q4FY26, compared with a one-time loss of ₹30.6 crore in the same quarter last year.

This swing alone changes comparability between the two quarters, especially when the base quarter had a significant non-recurring expense. Even without assigning a precise contribution split, the quarter’s narrative is clear: stronger operations were supplemented by a favourable exceptional item, amplifying the reported profit outcome.

Q4FY26 results vs brokerage preview ranges

The provided data also includes brokerages’ preview estimates for Q4FY26 from firms including MOFSL, YES Securities, and JM Financial. Those previews expected revenue in the range of ₹520 to ₹558 crore and profit after tax (PAT) in the range of ₹46 to ₹54 crore, with margin expectations of 9.5% to 11%.

Against those preview ranges, the reported Q4FY26 numbers show lower revenue (₹437 crore) but substantially higher net profit (₹108 crore) than the PAT range cited. The difference highlights how non-operating or exceptional items, accounting treatments, and consolidation factors can create large gaps between reported profitability and preview expectations.

Other quarterly figures mentioned in the provided data

Apart from the Q4FY26 performance, the data includes another set of quarterly financial numbers without a clear period label. It lists revenue at ₹321.46 crore (down 2.82% QoQ from ₹330.80 crore and up 9.90% YoY). Operating profit is stated at ₹25.16 crore (up 3.16% QoQ from ₹24.39 crore and down 24.35% YoY). PBDT is listed at ₹31.62 crore, while profit before tax is stated at ₹49.59 crore and net profit at ₹46.89 crore.

The same dataset also includes a separate reference to the quarter ending December 2024, describing PBT at ₹40.48 crore and PAT at ₹31.78 crore, along with an inventory turnover ratio of 3.72 times, EPS of ₹3.25, and cash and cash equivalents at ₹17.17 crore. Since these figures refer to different snapshots, readers should treat them as contextual datapoints rather than directly comparable to Q4FY26 without the underlying financial statement period definitions.

Management commentary from prior earnings calls (context)

In an earnings-call excerpt included in the data for Q4FY25 and FY25, management stated total revenue for the quarter at ₹338 crore, with 15% year-on-year growth, and full-year revenue at ₹1,310 crore, up 13%. The same excerpt cites gross margin at 69% for the quarter, up 200 basis points year-on-year.

It also mentions EBITDA of ₹84 crore for the quarter versus ₹73 crore a year ago, with an EBITDA margin of 25% for the quarter and 26% for the full year. Another line item referenced is a one-time exceptional item linked to settlement of pending litigation with Celtrion amounting to ₹29 crore.

Separately, an excerpt covering Q4FY24 and FY24 cites consolidated revenue of ₹294 crore for the quarter, EBITDA of ₹72.5 crore, and quarterly PAT of ₹24.5 crore. For FY24, it states revenue at ₹1,160 crore and EBITDA at ₹252.5 crore, with net debt at ₹912 crore and a QIP equity raise of ₹500 crore in April.

Market reaction context: strong results do not always lift the stock

The data also references an older episode from Q4FY20 when Shilpa Medicare’s shares fell 8.8% intraday on June 16 despite reporting a 45% year-on-year increase in profit to ₹34.57 crore. That quarter’s revenue rose 10% year-on-year to ₹220 crore, EBITDA grew 22% to ₹45 crore, and EBITDA margin expanded to 20.7%.

The example is a reminder that the market’s reaction depends on multiple factors beyond headline profit growth, including expectations, quality of earnings, one-off items, and broader risk sentiment.

Key numbers at a glance

Estimates vs reported: what the preview expected

Dates to track

Two different timing references appear in the provided data. One line says Shilpa Medicare scheduled its Q4 FY26 results for May 2026 (expected). Another line states the “upcoming earnings date” for Shilpa Medicare Ltd. is 6 February 2026. Since both appear in the same dataset, investors typically cross-check the company’s exchange filings and investor communications for the confirmed schedule.

Conclusion

Shilpa Medicare’s Q4FY26 results show a sharp year-on-year increase in net profit to ₹108 crore, driven by 32% revenue growth, EBITDA margin expansion to 27.4%, and a swing to a ₹25 crore one-time gain. The next key checkpoint will be confirmed company communication on the earnings schedule mentioned in the data and any further detail on what drove the quarter’s operating and exceptional-item movements.